Clinical trials: Schizophrenic Disorder
Schizophrenias, Psychoses
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
The purpose of this study is to determine whether preventative treatment with sarcosine can reduce symptoms and delay/avoid disease progression in individuals defined as being in a prodromal stage of schizophrenia.
- Conditions
- Schizophrenias, Psychoses, Psychotic Disorders, Schizophrenic Disorders
- Trial name
- NCT00276263
- Testing
- Sarcosine (N-methylglycine)
- Where
- 2 sites in Israel
- Sponsor
- Herzog Hospital
Schizophrenic Disorder
SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia
The purpose of this 6-week study is to determine whether treatment with Seroquel® Sustained Release (SR) is more effective than placebo in the treatment of acute schizophrenia.
- Trial name
- NCT00206115
- Testing
- Seroquel Sustained Release (SR), Seroquel Immediate Release (IR)
- Where
- 31 sites in Bulgaria, Greece and 6 more
- Volunteers
- 535 people
- Sponsor
- AstraZeneca
Schizophrenic Disorders
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
The trial is designed to assess the long term subjective well-being in schizophrenic outpatients treated with quetiapine XR (extended release) or oral risperidone at flexible dose in a naturalistic setting over a period of one…
- Trial name
- RECOVER (NCT00600756)
- Testing
- Quetiapine XR, Risperidone
- Where
- 116 sites in Belgium, Brazil and 12 more
- Volunteers
- 798 people
- Sponsor
- AstraZeneca
Schizophrenic Disorders
The Psychiatric Rehabilitation Approach to Weight Loss
The primary aim of the project is to examine the efficacy of the Psychiatric Rehabilitation Weight Loss program in reduction of weight and body mass index (BMI.
- Trial name
- NCT00572247
- Testing
- Psychiatric Rehabilitation Approach to Weight Loss
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- University of Kansas
Schizophrenic Disorders, Schizoaffective Disorder
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot.
- Trial name
- NCT00088465
- Testing
- Intramuscular olanzapine depot
- Where
- 92 sites in United States, Argentina and 23 more
- Volunteers
- 931 people
- Sponsor
- Eli Lilly and Company
Schizophrenias, Psychoses
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
Adjuvant N-methyl-D-aspartic acid (NMDA)-enhancing agents, such as GlyT-1 inhibitors and NMDA-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia patients.
- Conditions
- Schizophrenias, Psychoses, Psychotic Disorders, Schizophrenic Disorders
- Trial name
- NCT00960219
- Testing
- D-amino acid oxidase inhibition (DAAOI-1)
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- China Medical University Hospital
Schizophrenia, Schizophrenic Disorders
Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia
augmentation of clozapine with paliperidone in the treatment of resistant schizophrenia has not been tested until now in randomized controlled trials.
- Conditions
- Schizophrenia, Schizophrenic Disorders, Psychotic Disorder
- Trial name
- NCT01279213
- Testing
- paliperidone clozapine
- Where
- Argentina
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional de Rosario
Schizophrenic Disorders
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and…
- Trial name
- NCT00660595
- Testing
- Quetiapine, Risperidone
- Where
- 4 sites in Finland
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizophrenic Disorder
Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome
The goal of this research program is to implement a series of psychoeducational training classes designed to teach individuals with schizophrenia the importance of medication treatment, how to identify and manage medication side…
- Trial name
- NCT00018837
- Testing
- Community Re-Entry Program: What is Schizophrenia
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Schizophrenias, Psychoses
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
Both GlyT-1 inhibitors and NMDA-glycine site agonists have been demonstrated to be beneficial for chronic schizophrenia patients.
- Conditions
- Schizophrenias, Psychoses, Psychotic Disorders, Schizophrenic Disorders
- Trial name
- NCT00491569
- Testing
- Sarcosine and D-serine
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- China Medical University Hospital
Schizophrenic Disorders
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine; evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine…
- Trial name
- NCT00088491
- Testing
- Intramuscular Olanzapine Depot, Oral Olanzapine
- Where
- 4 sites in Finland, Turkey (Türkiye)
- Volunteers
- 1,205 people
- Sponsor
- Eli Lilly and Company
Schizophrenic Disorders
Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
The purpose of this study is to develop the weight management program, which is combined with healthy diet, proper physical exercise, and behavior modification, related to patient's quality of life.
- Trial name
- NCT00485823
- Testing
- Olanzapine Hydrochloride, Weight Management Program
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Schizophrenias, Psychoses
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
The etiology of schizophrenia remains unclear. Schizophrenia patients reveal positive symptoms, negative symptoms, and cognitive impairments.
- Conditions
- Schizophrenias, Psychoses, Psychotic Disorders, Schizophrenic Disorders
- Trial name
- NCT00328276
- Testing
- Sarcosine
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- China Medical University Hospital
Schizophrenic Disorders
Psychological Intervention for Relapse Prevention in First Episode Schizophrenia
The study is a randomized clinical trial investigating the efficacy of a comprehensive psychological intervention for the treatment of first episode schizophrenia
- Trial name
- NCT00161408
- Testing
- cognitive behavioural therapy, psychoeducation
- Where
- 5 sites in Germany
- Volunteers
- 106 people
- Sponsor
- University Hospital Tuebingen